UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients
With Two Late-Stage Candidates
Executive Summary
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
You may also be interested in...
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
EU Approvals: Evenity Cleared For Severe Osteoporosis
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.